Authors

This educational activity has been developed by the Melanoma Research Foundation (MRF) and Mechanisms in Medicine Inc., with the assistance of the following Expert Faculty, who are experts in melanoma:

Dr. Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY
USA

Disclosure of Conflicts of Interest: Dr. Jeffrey S. Weber – Nothing to disclose.

Dr. Laura Ferris, MD, PhD
Professor and Director of Dermatology Clinical Trials
Department of Dermatology, University of Pittsburgh
Pittsburgh, Pennsylvania
USA

Disclosure of Conflicts of Interest: Dr. Laura Ferris – Consulting fees received from DermTech. Research funding received from Castle Biosciences.

Dr. Rekha Chaudhary, MD
Adjunct Associate Professor of Medicine, Division of Hematology Oncology
Adjunct Associate Professor of Neurology
University of Cincinnati
Cincinnati, Ohio
USA

Disclosure of Conflicts of Interest: Dr. Rekha Chaudhary – Speaker fees received from Bristol-Myers Squibb, Merck, Regeneron, and Sanofi.

Dr. Michael B. Atkins, MD
Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
William M. Scholl Professor and Vice-Chair Department of Oncology and
Professor of Medicine, Georgetown University Medical Center
Washington, DC
USA

Disclosure of Conflicts of Interest: Dr. Michael B. Atkins – Scientific Advisory Board: Werewolf and Pyxis Oncology; Consultant/Advisory Boards: Bristol Myers Squibb, Merck, Novartis, Eisai, Aveo, Pfizer, Werewolf, Fathom, Pyxis Oncology, PACT, Elpis, X4Pharma, ValoHealth, ScholarRock, Surface, Takeda, Roche, SAB Bio, Exelixis, Iovance, COTA, Idera, Agenus, Asher Bio, AstraZeneca, SeaGen, Sanofi, OncoRena, Pliant Therapeutics, GSK.

Dr. Sapna P. Patel, MD
Melanoma Medical Oncologist
Chair, SWOG Cancer Research Network
Houston, Texas
USA

Disclosure of Conflicts of Interest: Dr. Sapna P. Patel – Research funding received from: Bristol Myers Squibb, Foghorn Therapeutics, IDEAYA Biosciences, InxMed; Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Pharmaceuticals, TriSalus Life Sciences; Consulting fees received from: Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Delcath Systems, Immatics, Immunocore, Novartis, Pfizer, TriSalus Life Sciences. Travel and accommodations: InxMed, TriSalus Life Sciences.

This educational activity has been developed by the Melanoma Research Foundation (MRF), and Mechanisms in Medicine Inc.

This activity is supported by independent educational grants from Bristol-Myers Squibb, Foundation Medicine, Genentech, Iovance Biotherapeutics, Merck, Natera, and Novartis.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.